<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00926315</url>
  </required_header>
  <id_info>
    <org_study_id>FMUSPIBCCVD2009</org_study_id>
    <secondary_id>CAPPesq 626/06</secondary_id>
    <secondary_id>FAPESP 07/04799-2</secondary_id>
    <secondary_id>IBCC 108/2006/07</secondary_id>
    <secondary_id>CAPPesq 0018/09</secondary_id>
    <nct_id>NCT00926315</nct_id>
  </id_info>
  <brief_title>Gene Expression Profile of Breast Cancer Samples After Vitamin D Supplementation</brief_title>
  <official_title>Influence of Vitamin D on Gene Expression Profile of Breast Cancer Samples From Post-menopausal Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Brasileiro de Controle do Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether calcitriol supplementation may reduce tumor
      cell proliferation and influence gene expression profile of breast cancer samples from
      post-menopausal patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women affected by breast cancer present lower 1,25(OH)2D3 or 25(OH)D3 serum levels than
      unaffected ones. Calcitriol supplementation may be indicated to post-menopausal women to
      reduce bone loss. Vitamin D has antiproliferative effects in breast cancer cell lines and
      breast cancer xenografts.

      Post-menopausal breast cancer patients will be prescribed calcitriol supplementation, in
      doses indicated to prevent osteoporosis, while they are submitted to biopsy, staging exams
      and have their breast surgery scheduled (approximately one month). Tumor dimension and
      proliferation rate (as determined by Ki67 expression), 25(OH)D3 and/or 1,25(OH)2D3 serum
      concentration, will be evaluated before and after calcitriol supplementation. Tumor gene
      expression will be evaluated in samples collected before and after supplementation to analyze
      the differential profile.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor dimension and proliferation evaluated by ultrasound and Ki67 expression; Tumor gene expression profile</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Follow-up for 5 years</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Postmenopausal Disorder</condition>
  <arm_group>
    <arm_group_label>calcitriol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>calcitriol supplementation (0.25 mcg 2x/d)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calcitriol</intervention_name>
    <description>Post menopausal patients will receive Calcitriol 0.50 mcg PO per day for 1 month.</description>
    <arm_group_label>calcitriol</arm_group_label>
    <other_name>Rocaltrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitriol</intervention_name>
    <description>calcitriol 0.25 mcg PO bid</description>
    <arm_group_label>calcitriol</arm_group_label>
    <other_name>Rocaltrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women

          -  Invasive breast carcinoma

          -  Clinical conditions for breast surgery

          -  No previous neoadjuvant treatment for breast cancer

          -  Agreement to take part in the study and sign the informed consent

        Exclusion Criteria:

          -  History of hypercalcemia or nephrolithiasis

          -  Current use of corticosteroids, vitamin D supplementation, HRT

          -  Previous chemotherapy, hormonotherapy or radiotherapy

          -  Parathyroid disease

          -  Absence of clinical condition to receive supplementation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Aparecida A Koike Folgueira, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculdade de Medicina - Universidade de São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo Carneiro de Lyra, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Brasileiro de Controle do Cancer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuri N Urata, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculdade de Medicina da Universidade de São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Lucia H Katayama, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculdade de Medicina da Universidade de São Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Brasileiro de Controle do Câncer - IBCC</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>03102-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>de Lyra EC, da Silva IA, Katayama ML, Brentani MM, Nonogaki S, Góes JC, Folgueira MA. 25(OH)D3 and 1,25(OH)2D3 serum concentration and breast tissue expression of 1alpha-hydroxylase, 24-hydroxylase and Vitamin D receptor in women with and without breast cancer. J Steroid Biochem Mol Biol. 2006 Aug;100(4-5):184-92. Epub 2006 Jul 7.</citation>
    <PMID>16828283</PMID>
  </reference>
  <reference>
    <citation>Rozenchan PB, Folgueira MA, Katayama ML, Snitcovsky IM, Brentani MM. Ras activation is associated with vitamin D receptor mRNA instability in HC11 mammary cells. J Steroid Biochem Mol Biol. 2004 Sep;92(1-2):89-95.</citation>
    <PMID>15544934</PMID>
  </reference>
  <reference>
    <citation>Katayama ML, Pasini FS, Folgueira MA, Snitcovsky IM, Brentani MM. Molecular targets of 1,25(OH)2D3 in HC11 normal mouse mammary cell line. J Steroid Biochem Mol Biol. 2003 Jan;84(1):57-69.</citation>
    <PMID>12648525</PMID>
  </reference>
  <reference>
    <citation>Bortman P, Folgueira MA, Katayama ML, Snitcovsky IM, Brentani MM. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on breast cells: a mini review. Braz J Med Biol Res. 2002 Jan;35(1):1-9. Review.</citation>
    <PMID>11743608</PMID>
  </reference>
  <reference>
    <citation>Folgueira MA, Federico MH, Katayama ML, Silva MR, Brentani MM. Expression of vitamin D receptor (VDR) in HL-60 cells is differentially regulated during the process of differentiation induced by phorbol ester, retinoic acid or interferon-gamma. J Steroid Biochem Mol Biol. 1998 Aug;66(4):193-201.</citation>
    <PMID>9744516</PMID>
  </reference>
  <reference>
    <citation>Janjoppi L, Katayama MH, Scorza FA, Folgueira MA, Brentani M, Pansani AP, Cavalheiro EA, Arida RM. Expression of vitamin D receptor mRNA in the hippocampal formation of rats submitted to a model of temporal lobe epilepsy induced by pilocarpine. Brain Res Bull. 2008 Jul 30;76(5):480-4. doi: 10.1016/j.brainresbull.2008.01.002. Epub 2008 Feb 5.</citation>
    <PMID>18534255</PMID>
  </reference>
  <reference>
    <citation>Folgueira MA, Carraro DM, Brentani H, Patrão DF, Barbosa EM, Netto MM, Caldeira JR, Katayama ML, Soares FA, Oliveira CT, Reis LF, Kaiano JH, Camargo LP, Vêncio RZ, Snitcovsky IM, Makdissi FB, e Silva PJ, Góes JC, Brentani MM. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res. 2005 Oct 15;11(20):7434-43.</citation>
    <PMID>16243817</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2009</study_first_submitted>
  <study_first_submitted_qc>June 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2009</study_first_posted>
  <last_update_submitted>October 31, 2012</last_update_submitted>
  <last_update_submitted_qc>October 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo General Hospital</investigator_affiliation>
    <investigator_full_name>Eduardo Carneiro de Lyra</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Calcitriol</keyword>
  <keyword>Postmenopausal</keyword>
  <keyword>Cell Proliferation</keyword>
  <keyword>Gene Expression Profiling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

